Underwriting AgreementUnderwriting Agreement • September 1st, 2020 • Odonate Therapeutics, Inc. • Pharmaceutical preparations • New York
Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,614,036 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 842,105 additional shares (the “Optional Shares”) of common stock, par value $0.01 per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares.”
OPEN MARKET SALE AGREEMENTSMOdonate Therapeutics, Inc. • February 23rd, 2021 • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • November 27th, 2017 • Odonate Therapeutics, LLC • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is entered into as of November [ ], 2017 (the “Effective Date”) by and between Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Indemnitee”).
LIMITED LIABILITY COMPANY AGREEMENT OF ODONATE HOLDINGS, LLCLimited Liability Company Agreement • February 14th, 2018 • Odonate Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Limited Liability Company Agreement (this “Operating Agreement”) of Odonate Holdings, LLC (“Odonate Holdings”) is made effective as of December 6, 2017 (the “Effective Date”), with respect to the holders of Units (each a “Member,” and collectively, the “Members”). This Operating Agreement amends and restates that certain Limited Liability Company Agreement, dated as of November 27, 2017 (the “Prior Agreement”).
LICENSE AGREEMENT BETWEEN DAIICHI SANKYO COMPANY, LIMITED AND ODONATE THERAPEUTICS, LLC1License Agreement • November 13th, 2017 • Odonate Therapeutics, LLC • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”), dated the 3rd day of June, 2013, is between DAIICHI SANKYO COMPANY, LIMITED, a Japanese corporation having an office and principal place of business at 5-1, Nihonbashi-honcho 3-chome Chuo-ku, Tokyo 103-8426, Japan (“Daiichi Sankyo”), and Odonate Therapeutics, LLC, a Delaware limited liability company having an office and principal place of business at 4747 Executive Drive, Suite 510, San Diego, California 92121 (“Odonate”). Daiichi Sankyo and Odonate are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
